ARIKAYCE®

About PARI Pharma

PARI Pharma is a long-established, privately-held German company that has evolved into a leading partner for inhaled drug development, leveraging its proprietary eFlow mesh nebulizer technology. It operates as a contract development and manufacturing organization (CDMO) for respiratory therapeutics, offering end-to-end support from device customization to regulatory strategy and commercial supply. With over 20 years of experience in mesh nebulization, PARI supports a robust pipeline of partner programs, including several in late-stage clinical trials, targeting complex respiratory diseases like non-CF bronchiectasis, pulmonary fibrosis, and bronchiolitis obliterans syndrome.

About Insmed

Insmed is a patient-centric, global biopharma leader with a mission to deliver transformative therapies for serious and rare diseases. The company has achieved significant commercial and clinical milestones, including regulatory approvals and advanced late-stage pipelines, underpinned by a culture consistently recognized as a top employer. Its strategy hinges on deep patient collaboration, a synergistic technology platform spanning drug delivery and small molecules, and a disciplined focus on high-need pulmonary and rare disease markets.

Therapeutic Areas